Zhitong Finance App News, Rongchang Biotech (09995) issued an announcement. Currently, the company's production and operation are all normal, the supply chain is stable, the production capacity guarantee is sufficient, the commercialization of core products is progressing steadily, and the overall quality of operation continues to improve.
In terms of performance: In the first half of 2026, the company achieved operating income of 5.853 billion yuan, an increase of 433.11%; achieved net profit attributable to shareholders of listed companies of 4.662 billion yuan, a loss of 450 million yuan in the same period last year, turning a loss into a profit; net cash flow from operating activities was 4.214 billion yuan, compared to -246 million yuan in the same period last year, and profit quality and operational resilience continued to improve.
Core product progress:
(1) Titacip (RC18, trade name: Taiai): As of June 2026, titacip has been approved for five major indications in China: systemic lupus erythematosus, rheumatoid arthritis, systemic myasthenia gravis, dry syndrome, and immunoglobulin A nephropathy. Among them, the immunoglobulin A nephropathy indication was conditionally approved by the National Drug Administration (NMPA) in June 2026, and is the world's first dual-target biopharmaceutical approved to treat IgA nephropathy; it was approved at the same time, and the world's first dual-target innovative drug project to successfully complete phase III clinical trials and achieve strong positive results. In July 2026, injectable titacipr was successfully included in the “National List of Essential Medicines (2026 Edition)” and “Immune System Medication”. The new catalogue includes a total of 2 domestically produced Class I bioinnovative drugs. Taytacip is one of them, further improving drug accessibility and consolidating the market foundation in the field of autoimmunity.
(2) Virdicitumab (RC48, trade name: Edicitumab): In 2026, verdicitumab made important new progress in expanding its indications. In March, it was approved for marketing in the treatment of adult breast cancer with low HER2 expression and liver metastasis; in April, it was approved for the first-line treatment of her2 expressed locally advanced or metastatic urothelial cancer, making it the first HER2-ADC drug approved in the world.
Internationalization and BD cooperation: In January 2026, the company and AbbVie signed an exclusive licensing agreement for RC148, receiving a down payment of US$650 million, and is eligible to receive a maximum milestone payment of US$4.95 billion and a double-digit sales share; up to now, the company has completed global licensing of the four core drugs tetracip, verdicitumab, RC28, and RC148, with a cumulative total of over US$12.6 billion, and the internationalization strategy continues to be implemented.
In the future, the company will continue to focus on core treatment fields such as self-prevention and oncology, adhere to innovation at the source, steadily advance the clinical research and commercialization process of core products, and continue to enrich the product pipeline layout; at the same time, actively promote international strategies, deepen external licensing and global cooperation, and enhance market competitiveness. The company will also continue to strengthen R&D and production capacity building, optimize business quality and operational efficiency, fulfill information disclosure obligations in strict accordance with laws and regulations, and strive to create long-term value for shareholders.